This is a manually curated overview of research projects on COVID-19 which are funded by major funding agencies in Sweden. New projects are added on an ongoing basis. If you would like your project to be listed here, please get in touch with us (datacentre@scilifelab.se). See also SweCRIS, a database of all funded research projects in Sweden, where it is possible to search using custom keywords.
A list of all ethically approved clinical studies on COVID-19 in Sweden up until October 2020 can be found here (only in Swedish).
Last updated: 2020.12.07
Swedish Research Council
Screening for high amounts of SARS-CoV-2 identifies pre-symptomatic subjects among healthy healthcare workers
Dillner J,
Elfström KM,
Blomqvist J,
Engstrand L,
Uhlén M,
Eklund C,
Boulund F,
Lagheden C,
[...], Lundgren KC
[preprint] medRxiv (2020). DOI: 10.1101/2020.12.13.20248122
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.
Moliner-Morro A,
J Sheward D,
Karl V,
Perez Vidakovics L,
Murrell B,
McInerney GM,
Hanke L
Biomolecules 10 (12) (2020). DOI: 10.3390/biom10121661
Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity
Cagigi A,
Yu M,
Falck-Jones S,
Vangeti S,
Österberg B,
Åhlberg B,
Azizmohammadi V,
Falck-Jones R,
[...], Smed-Sörensen A
[preprint] medRxiv (2020). DOI: 10.1101/2020.11.25.20238592
Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.
Ng H,
Havervall S,
Rosell A,
Aguilera K,
Parv K,
von Meijenfeldt F,
Lisman T,
Mackman N,
[...], Phillipson M
Arterioscler Thromb Vasc Biol. (2020). DOI: 10.1161/ATVBAHA.120.315267
Deciphering the ins and outs of SARS-CoV-2-specific T cells.
Perez-Potti A,
Lange J,
Buggert M
Nat Immunol (2020). DOI: 10.1038/s41590-020-00838-5
Beyond chronological age: Frailty and multimorbidity predict in-hospital mortality in patients with coronavirus disease 2019.
Marengoni A,
Zucchelli A,
Vetrano DL,
Armellini A,
Botteri E,
Nicosia F,
Romanelli G,
Beindorf EA,
[...], Onder G
J Gerontol A Biol Sci Med Sci (2020). DOI: 10.1093/gerona/glaa291
The known unknowns of T cell immunity to COVID-19.
Karlsson AC,
Humbert M,
Buggert M
Sci Immunol 5 (53) (2020). DOI: 10.1126/sciimmunol.abe8063
Perturbations in the mononuclear phagocyte landscape associated with COVID-19 disease severity
Kvedaraite E,
Hertwig L,
Indranil S,
Ponzetta A,
Hed Myrberg I,
Magdalini Lourda M,
Dzidic M,
Akber M,
[...], Svensson M
[preprint] medRxiv (2020). DOI: 10.1101/2020.08.25.20181404
Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection
Sherina N,
Piralla A,
Du L,
Wan H,
Kumagai-Braesh M,
Andréll J,
Braesch-Andersen S,
Cassaniti I,
[...], Pan-Hammarström Q
[preprint] (2020). DOI: 10.1101/2020.11.06.371617
Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses.
Sperk M,
van Domselaar R,
Rodriguez JE,
Mikaeloff F,
Sá Vinhas B,
Saccon E,
Sönnerborg A,
Singh K,
[...], Neogi U
J Proteome Res 19 (11) 4259-4274 (2020). DOI: 10.1021/acs.jproteome.0c00380
Innate lymphoid cell composition associates with COVID-19 disease severity
García M,
Kokkinou E,
Carrasco García A,
Parrot T,
Palma Medina LM,
Maleki KT,
Christ W,
Varnaitė R,
[...], Group tKKCS
Clin Transl Immunol 9 (12) (2020). DOI: 10.1002/cti2.1224
Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care.
Hägg S,
Jylhävä J,
Wang Y,
Xu H,
Metzner C,
Annetorp M,
Garcia-Ptacek S,
Khedri M,
[...], Religa D
J Am Med Dir Assoc 21 (11) 1555-1559.e2 (2020). DOI: 10.1016/j.jamda.2020.08.014
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC,
Pires da Silva BGP,
Fonseca BAL,
Fonseca NP,
Auxiliadora-Martins M,
Mastaglio S,
Ruggeri A,
Sironi M,
[...], Lambris JD
Clin Immunol 220 108598 (2020). DOI: 10.1016/j.clim.2020.108598
Impact of COVID-19-Related Lockdown on Psychosocial, Cognitive, and Functional Well-Being in Adults With Down Syndrome.
Villani ER,
Vetrano DL,
Damiano C,
Paola AD,
Ulgiati AM,
Martin L,
Hirdes JP,
Fratiglioni L,
[...], Carfì A
Front Psychiatry 11 578686 (2020). DOI: 10.3389/fpsyt.2020.578686
Decline in mortality among hospitalised covid-19 patients in Sweden: a nationwide observational study
Strålin K,
Wahlström E,
Walther S,
Bennet-Bark AM,
Heurgren M,
Lindén T,
Holm J,
Hanberger H
[preprint] medRxiv (2020). DOI: 10.1101/2020.10.27.20220061
Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past infection during virus emergence in Sweden
Castro Dopico X,
Hanke L,
Sheward DJ,
Muschiol S,
Aleman S,
Christian M,
Grinberg NF,
Adori M,
[...], Karlsson Hedestam GB
[preprint] medRxiv (2020). DOI: 10.1101/2020.07.17.20155937
Estimating total excess mortality during a COVID-19 outbreak in Stockholm, Sweden.
Pimenoff VN,
Elfström M,
Baussano I,
Björnstedt M,
Dillner J
Clin Infect Dis (2020). DOI: 10.1093/cid/ciaa1593
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
Sekine T,
Perez-Potti A,
Rivera-Ballesteros O,
Strålin K,
Gorin J,
Olsson A,
Llewellyn-Lacey S,
Kamal H,
[...], Buggert M
Cell 183 (1) 158-168.e14 (2020). DOI: 10.1016/j.cell.2020.08.017
High excess mortality in areas with young and socially vulnerable populations during the COVID-19 outbreak in Stockholm Region, Sweden.
Calderón-Larrañaga A,
Vetrano DL,
Rizzuto D,
Bellander T,
Fratiglioni L,
Dekhtyar S
BMJ Glob Health 5 (10) (2020). DOI: 10.1136/bmjgh-2020-003595
MAIT cell activation and dynamics associated with COVID-19 disease severity.
Parrot T,
Gorin J,
Ponzetta A,
Maleki KT,
Kammann T,
Emgård J,
Perez-Potti A,
Sekine T,
[...], Sandberg JK
Sci Immunol 5 (51) (2020). DOI: 10.1126/sciimmunol.abe1670
Antibodies to SARS-CoV-2 and risk of future sickness
Dillner J,
Elfström M,
Blomqvist J,
Eklund C,
Lagheden C,
Nordqvist-Kleppe S,
Hellström C,
Olofsson J,
[...], Conneryd Lundgren K
[preprint] medRxiv (2020). DOI: 10.1101/2020.09.14.20194308
Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity
Falck-Jones S,
Vangeti S,
Yu M,
Falck-Jones R,
Cagigi A,
Badolati I,
Osterberg B,
Lautenbach MJ,
[...], Smed-Sorensen A
[preprint] medRxiv (2020). DOI: 10.1101/2020.09.08.20190272
Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K,
Lipcsey M,
Andersson H,
Pontén E,
Bülow Anderberg S,
Gradin A,
Larsson A,
Lubenow N,
[...], Frithiof R
J Crit Care 60 249-252 (2020). DOI: 10.1016/j.jcrc.2020.08.026
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study.
Shi C,
Wang C,
Wang H,
Yang C,
Cai F,
Zeng F,
Cheng F,
Liu Y,
[...], Zhang Y
Clin Transl Sci (2020). DOI: 10.1111/cts.12880
Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients
Hultström M,
Frithiof R,
Eriksson O,
Persson B,
Lipcsey M,
Ekdahl KN,
Nilsson B
Thromb Haemost (2020). DOI: 10.1055/s-0040-1715835
SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study.
Hagman K,
Hedenstierna M,
Gille-Johnson P,
Hammas B,
Grabbe M,
Dillner J,
Ursing J
Clin Infect Dis (2020). DOI: 10.1093/cid/ciaa1285
Natural killer cell immunotypes related to COVID-19 disease severity.
Maucourant C,
Filipovic I,
Ponzetta A,
Aleman S,
Cornillet M,
Hertwig L,
Strunz B,
Lentini A,
[...], Karolinska COVID-19 Study Group
Sci Immunol 5 (50) (2020). DOI: 10.1126/sciimmunol.abd6832
A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.
Britton T,
Ball F,
Trapman P
Science 369 (6505) 846-849 (2020). DOI: 10.1126/science.abc6810
Blood type A associates with critical COVID-19 and death in a Swedish cohort.
Hultström M,
Persson B,
Eriksson O,
Lipcsey M,
Frithiof R,
Nilsson B
Crit Care 24 (1) 496 (2020). DOI: 10.1186/s13054-020-03223-8
Key questions for modelling COVID-19 exit strategies.
Thompson RN,
Hollingsworth TD,
Isham V,
Arribas-Bel D,
Ashby B,
Britton T,
Challenor P,
Chappell LHK,
[...], Restif O
Proc Biol Sci 287 (1932) 20201405 (2020). DOI: 10.1098/rspb.2020.1405
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
Eimer J,
Vesterbacka J,
Svensson AK,
Stojanovic B,
Wagrell C,
Sönnerborg A,
Nowak P
J Intern Med (2020). DOI: 10.1111/joim.13162
Social determinants of health and inequalities in COVID-19.
Burström B,
Tao W
Eur J Public Health 30 (4) 617-618 (2020). DOI: 10.1093/eurpub/ckaa095
Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.
Hammarström L,
Abolhassani H,
Baldanti F,
Marcotte H,
Pan-Hammarström Q
J Allergy Clin Immunol 146 (1) 58-60 (2020). DOI: 10.1016/j.jaci.2020.04.043
Heparin - An old drug with multiple potential targets in Covid-19 therapy.
Lindahl U,
Li JP
J Thromb Haemost (2020). DOI: 10.1111/jth.14898
Bats and humans
Sönnerborg A
Lakartidningen 117 (2020).
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs.
Neogi U,
Hill KJ,
Ambikan AT,
Heng X,
Quinn TP,
Byrareddy SN,
Sönnerborg A,
Sarafianos SG,
[...], Singh K
Pathogens 9 (5) (2020). DOI: 10.3390/pathogens9050320
Covid-19 – uppdatering om klinisk bild och behandling
Glans H,
Sönnerborg A,
Aleman S
Lakartidningen 117 (2020).
SciLifeLab / Knut and Alice Wallenberg Foundation
scilifelab.se / kaw.wallenberg.org
| Project title | Area | Principal investigator | PI affiliation | Duration |
|---|---|---|---|---|
| Uppsala COVID-19 ICU Biobank | Biobanks | Michael Hultström | Uppsala University | 2020 - 2021 |
| Building Capacity - the Sahlgrenska Covid-19 Biobank | Biobanks | Magnus Gisslén | University of Gothenburg | 2020 - 2021 |
| COVID-UMU: Sample collection and understanding the transition from mild to severe COVID-19 | Biobanks | Clas Ahlm | Umeå University | 2020 - 2021 |
| Assessment of SARS-CoV-2 specific antibodies in adults, and building a repository of samples from seroconverted asymptomatic adults | Biobanks | Åsa Torinsson Naluai | University of Gothenburg | 2020 - 2021 |
| The spread of SARS-CoV-2 monitored by the serum samples routinely obtained through maternal screening and blood donor screening | Biobanks | Martin Sundqvist | Örebro University | 2020 - 2021 |
| The COMMUNITY Study- COVID-19 Biomarker and Immunity Study | Biobanks | Charlotte Thålin | Karolinska Institute / Danderyd Hospital | 2020 - 2021 |
| Establishing a biobank of clinical specimens for studying evolution of viral diversity and development of immune response, including inflammation, seroprevalence and protective antibodies, in SARS-Cov2 infection (Biobank) | Biobanks | Patrik Medstrand | Lund University | 2020 - 2021 |
| A biomarker-based approach to rapidly identify COVID-19 patients at high risk of severe disease and mortality at 3 emergency departments in Region Skåne | Biobanks | Toralph Ruge | Lund University | 2020 - 2021 |
| Simple and cheap remote test for infection based on HCR | Diagnostics for virus | Björn Högberg | Karolinska Institute | 2020 - 2021 |
| COVID-19 screening test design | Diagnostics for virus | Masood Kamali-Moghaddam | Uppsala University | 2020 - 2021 |
| iLACO-Sweden | Diagnostics for virus | Vicent Pelechano | Karolinska Institute | 2020 - 2021 |
| Extraction-free high-sensitive RT assay for SARS-CoV-2 RNA detection | Diagnostics for virus | Björn Reinius | Karolinska Institute | 2020 - 2021 |
| RCA-COVID-DIA | Diagnostics for virus | Mats Nilsson | Stockholm University | 2020 - 2021 |
| COVseq – Developing COVseq for mass-scale SARS-CoV-2 sequencing | Viral sequence evolution | Nicola Crosetto | Karolinska Institute | 2020 - 2021 |
| A community resource for SARS-CoV-2 structure, interactome and evolution | Viral sequence evolution | Arne Elofsson | Stockholm University | 2020 - 2021 |
| Rapid cDNA and direct RNA sequencing of SARS-CoV-2 using Oxford Nanopore | Viral sequence evolution | Lars Feuk | Uppsala University | 2020 - 2021 |
| Analysis of essential genes and validity as drug targets | Viral sequence evolution | Tomas Nyman | Stockholm University | 2020 - 2021 |
| Optimized expression of the SARS-Cov-2 Spike protein in mammalian cells for serology testing and functional studies | High-throughput and high-contents serology | Fredrik Sterky | University of Gothenburg | 2020 - 2021 |
| Production of SARS-CoV-2 surface proteins in HEK293 cells* | High-throughput and high-contents serology | Juni Andréll | Stockholm University | 2020 - 2021 |
| Biological investigations of Covid-19 in cancer patients | High-throughput and high-contents serology | Gunilla Enblad | Uppsala University | 2020 - 2021 |
| Peptides for serological test of COVID-19 antibodies and as molecular tools | High-throughput and high-contents serology | Ulf Göransson | Uppsala University | 2020 - 2021 |
| Seroprevalence and predictors of COVID-19 disease severity in two areas of Sweden | High-throughput and high-contents serology | Anne Lindberg | Umeå University | 2020 - 2021 |
| Large-scale production of a bio-safe antigen of COVID-19 and chimeric bat coronaviruses | High-throughput and high-contents serology | Kenta Okamoto | Uppsala University | 2020 - 2021 |
| Translational serology for a population-wide assessment of Covid19 immunity | High-throughput and high-contents serology | Jochen Schwenk | KTH Royal Institute of Technology | 2020 - 2021 |
| Multiplex analysis of immune response against Covid-19 | High-throughput and high-contents serology | Sofia Hober | KTH Royal Institute of Technology | 2020 - 2021 |
| Rapid development of novel antibody assays diagnosing Covid-19 | High-throughput and high-contents serology | Jan-Åke Liljeqvist | University of Gothenburg | 2020 - 2021 |
| Human antibodies against the SARS-CoV-2 spike protein | High-throughput and high-contents serology | Mats Ohlin | Lund University | 2020 - 2021 |
| Characterization of the B cell response during SARS-CoV-2 infection | High-throughput and high-contents serology | Karin Loré | Karolinska Institute | 2020 - 2021 |
| PLA-based large-scale analysis of Corona virus immunity | High-throughput and high-contents serology | Ulf Landegren | Uppsala University | 2020 - 2021 |
| Neutralizing human B-cell derived monoclonal antibodies to SARS-CoV-2 | High-throughput and high-contents serology | Pontus Nordenfelt | Lund University | 2020 - 2021 |
| SICoV – Serological Investigations on SARS-CoV-2 and other coronaviruses – improveddiagnostics and knowledge | High-throughput and high-contents serology | Åke Lundkvist | Uppsala University | 2020 - 2021 |
| Covid-19 patients | Biomarkers and systems biology | Jacob Odeberg | KTH Royal Institute of Technology | 2020 - 2021 |
| Prediction of severe disease in Covid-19 | Biomarkers and systems biology | Lars-Magnus Andersson | University of Gothenburg | 2020 - 2021 |
| Taking back the control of the SARS-CoV2 antiviral immune response as a mean to neutralize the COVID19 disease pathogenicity | Biomarkers and systems biology | Marie Larsson | Linköping University | 2020 - 2021 |
| Systems immunology analyses of the cytokine storm in COVID-19 | Biomarkers and systems biology | Petter Brodin | Karolinska Institute | 2020 - 2021 |
| Establishing a biobank of clinical specimens for studying evolution of viral diversity and development of immune response, including inflammation, seroprevalence and protective antibodies, in SARS-Cov2 infection (Research project) | Biomarkers and systems biology | Patrik Medstrand | Lund University | 2020 - 2021 |
| Dynamics and longevity of the specific adaptive immune response in COVID-19 patient | Biomarkers and systems biology | Davide Angeletti | University of Gothenburg | 2020 - 2021 |
| Immediate molecular response to SARS-CoV-2 infection | Host cell systems biology and targets | Jonas Klingström | Karolinska Institute | 2020 - 2021 |
| Mapping SARS-CoV-2 host-pathogen interactions for drug repurposing | Host cell systems biology and targets | Ylva Ivarsson | Uppsala University | 2020 - 2021 |
| Viral-host interaction of SARS-CoV-2 protein corona | Host cell systems biology and targets | Maria Pernemalm | Karolinska Institute | 2020 - 2021 |
| Profiling of host proteins associated to the envelope of SARS-CoV-2 | Host cell systems biology and targets | Claudia Fredolini | KTH Royal Institute of Technology | 2020 - 2021 |
| Genetic screens to identify novel determinants of SARS-CoV-2 infection | Host cell systems biology and targets | Oscar Fernandez-Capetillo | Karolinska Institute | 2020 - 2021 |
| Cellular thermal shift assay (CETSA) to identify host factors involved in SARS-CoV-2 entry and replication | Host cell systems biology and targets | Leo Hanke | Karolinska Institute | 2020 - 2021 |
| Identification of host factors targeted by coronaviruses by Thermal proteome profiling | Host cell systems biology and targets | Oscar Fernandez-Capetillo | Karolinska Institute | 2020 - 2021 |
| Creating synthetic biology tools to reveal the determinants of SARS-CoV-2 interactions with host cells | Host cell systems biology and targets | Erdinc Sezgin | Karolinska Institute | 2020 - 2021 |
| Human precision cut lung slices as an ex vivo model for studying SARS-CoV2 infection and identifying potential therapies | Host cell systems biology and targets | Darcy Wagner | Lund University | 2020 - 2021 |
| Identifying the Achilles heel of SARS-CoV-2 by using gene scissors | Host cell systems biology and targets | Claudia Kutter | KTH Royal Institute of Technology | 2020 - 2021 |
| NEVERMORE COVID – Establishing a drug discovery platform for corona virus disease | Drug discovery and repurposing of drugs | Kristian Sandberg | Uppsala University | 2020 - 2021 |
| A high-quality drug repurposing set | Drug discovery and repurposing of drugs | Anna-Lena Gustavsson | Karolinska Institute | 2020 - 2021 |
| Multi-level profiling of Coronavirus-infected cells by combining Viral Entry Assays, Cell Painting, and DrugSEQ | Drug discovery and repurposing of drugs | Ola Spjuth | Uppsala University | 2020 - 2021 |
| Spatial single cell mapping of SARS-CoV-2 interacting host proteins for quick and targeted drug repurposing | Drug discovery and repurposing of drugs | Charlotte Stadler | KTH Royal Institute of Technology | 2020 - 2021 |
| FragCor – Fragment based NMR screen targeting SARS-Cov-2 proteins | Drug discovery and repurposing of drugs | Göran Karlsson | University of Gothenburg | 2020 - 2021 |
| An adaptable therapeutic technology platform to treat SARS-CoV infections in immune suppressed individuals | Drug discovery and repurposing of drugs | Sara Mangsbo | Uppsala University | 2020 - 2021 |
| Rapid testing for treatment of Covid-19 | Drug discovery and repurposing of drugs | Kristina Nyström | Sahlgrenska University Hospital | 2020 - 2021 |
| Discovery of SARS-CoV-2 Inhibitors by Virtual Screening of Ultra-large Chemical Space | Drug discovery and repurposing of drugs | Jens Carlsson | Uppsala University | 2020 - 2021 |
| Chemographic characterization of compounds binding to seven identified molecular targets from SARS-CoV-2 | Drug discovery and repurposing of drugs | Anders Backlund | Uppsala University | 2020 - 2021 |
| Distributed computing to generate the druggable conformational ensemble of sars-cov-2 proteins | Drug discovery and repurposing of drugs | Lucie Delemotte | KTH Royal Institute of Technology | 2020 - 2021 |
| ARS-CoV-2 in sewage water as a tool for monitoring the potential circulation of the viruses in the population and rate of infections (SARS-CoV-2) | Environmental virus profiling | Zeynep Cetecioglu Gurol | KTH Royal Institute of Technology | 2020 - 2021 |
| Sewage as a proxy for SARS-CoV2 prevalence | Environmental virus profiling | Maja Malmberg | Swedish Agricultural University | 2020 - 2021 |
| Detection, monitoring and genetic evaluation of SARS-CoV2 in wastewater treatment plants | Environmental virus profiling | Anna J. Székely | Uppsala University | 2020 - 2021 |
| Surface persistence and SARS-CoV-2 exposure in the Stockholm Subway | Environmental virus profiling | Klas Udekwu | Swedish Agricultural University | 2020 - 2021 |
| A multi-level digital twin framework for Covid-19: from mechanisms of disease ethiology, to clinical decision-support and epidemiology | Data-driven research models and AI | Gunnar Cedersund | Linköping University | 2020 - 2021 |
| Building a platform with AI models, datasets and web applications for fighting COVID-19 | Data-driven research models and AI | Emma Lundberg | KTH Royal Institute of Technology | 2020 - 2021 |
| Artificial intelligence-based knowledge curation to direct COVID-19 research and public health efforts | Data-driven research models and AI | Sonja Aits | Lund University | 2020 - 2021 |
| COVID-19 – a population-based project of ICU patients | Data-driven research models and AI | Emma Larsson (will be combined with project below) | Karolinska Institute | 2020 - 2021 |
| Characterization of ICU treated COVID patients in Sweden | Data-driven research models and AI | Jonathan Grip (will be combined with project above) | Karolinska Institute | 2020 - 2021 |
| Rapid testing of SARS-Cov-2 in national coordination with health care | Program for SARS-CoV-2 virus testing | Lars Engstrand | Karolinska Institute | 2020 - 2021 |
| Development of high-throughput serology testing capability | Program for SARS-CoV-2 virus testing | Peter Nilsson, Sophia Hober | KTH Royal Institute of Technology | 2020 - 2021 |
| Sampling of COVID-19 patients for analysis of disease pathogenesis | Program for SARS-CoV-2 virus testing | Hans-Gustaf Ljunggren | Karolinska University Hospital | 2020 - 2021 |
Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients
Bülow Anderberg S,
Luther T,
Berglund M,
Larsson R,
Rubertsson S,
Lipcsey M,
Larsson A,
Frithiof R,
[...], Hultström M
Cytokine 138 155389 (2021). DOI: 10.1016/j.cyto.2020.155389
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
Havervall S,
Jernbom Falk A,
Klingstrom J,
Ng H,
Greilert Norin N,
Gabrielsson L,
Salomonsson AC,
Isaksson E,
[...], Thalin C
[preprint] medRxiv (2021). DOI: 10.1101/2021.01.03.21249162
Elevated factor V activity and antigen levels in patients with COVID ‐19 are related to disease severity and 30‐day mortality
Meijenfeldt FA,
Havervall S,
Adelmeijer J,
Lundström A,
Magnusson M,
Mackman N,
Thalin C,
Lisman T
Am J Hematol (2021). DOI: 10.1002/ajh.26085
The Swedish COVID-19 intensive care cohort: Risk of ICU admission and ICU mortality.
Ahlström B,
Frithiof R,
Hultström M,
Larsson I,
Strandberg G,
Lipcsey M
Acta Anaesthesiologica Scandinavica in press (2021).
Screening for high amounts of SARS-CoV-2 identifies pre-symptomatic subjects among healthy healthcare workers
Dillner J,
Elfström KM,
Blomqvist J,
Engstrand L,
Uhlén M,
Eklund C,
Boulund F,
Lagheden C,
[...], Lundgren KC
[preprint] medRxiv (2020). DOI: 10.1101/2020.12.13.20248122
Serum neopterin levels in relation to mild and severe COVID-19
Robertson J,
Gostner JM,
Nilsson S,
Andersson L,
Fuchs D,
Gisslen M
Infect Dis . Dec 10; 20 (1) 942 (2020). DOI: 10.1101/2020.08.19.20178178
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality
Meijenfeldt FA,
Havervall S,
Adelmeijer J,
Lundström A,
Rudberg A,
Magnusson M,
Mackman N,
Thalin C,
[...], Lisman T
Res Pract Thromb Haemost (2020). DOI: 10.1002/rth2.12462
Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity
Cagigi A,
Yu M,
Falck-Jones S,
Vangeti S,
Österberg B,
Åhlberg B,
Azizmohammadi V,
Falck-Jones R,
[...], Smed-Sörensen A
[preprint] medRxiv (2020). DOI: 10.1101/2020.11.25.20238592
Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.
Ng H,
Havervall S,
Rosell A,
Aguilera K,
Parv K,
von Meijenfeldt F,
Lisman T,
Mackman N,
[...], Phillipson M
Arterioscler Thromb Vasc Biol. (2020). DOI: 10.1161/ATVBAHA.120.315267
Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality.
Rosell A,
Havervall S,
von Meijenfeldt F,
Hisada Y,
Aguilera K,
Grover SP,
Lisman T,
Mackman N,
[...], Thålin C
Arterioscler Thromb Vasc Biol ATVBAHA120315547 (2020). DOI: 10.1161/ATVBAHA.120.315547
The Impact of Viremia on Organ Failure, Biomarkers and Mortality in a Swedish Cohort of Critically ill COVID-19 Patients
Järhult JD,
Hultström M,
Bergqvist A,
Frithiof R,
Lipcsey M
[preprint] Research square (2020). DOI: 10.21203/rs.3.rs-115082/v1
Perturbations in the mononuclear phagocyte landscape associated with COVID-19 disease severity
Kvedaraite E,
Hertwig L,
Indranil S,
Ponzetta A,
Hed Myrberg I,
Magdalini Lourda M,
Dzidic M,
Akber M,
[...], Svensson M
[preprint] medRxiv (2020). DOI: 10.1101/2020.08.25.20181404
COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury.
Luther T,
Bülow-Anderberg S,
Larsson A,
Rubertsson S,
Lipcsey M,
Frithiof R,
Hultström M
Acta Anaesthesiol Scand (2020). DOI: 10.1111/aas.13746
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J,
Sánchez Nievas G,
Falcone M,
Youhanna S,
Richardson P,
Ottaviani S,
Shen JX,
Sommerauer C,
[...], Lauschke VM
Sci Adv (2020). DOI: 10.1126/sciadv.abe4724
Point-of-care detection of SARS-CoV-2 in nasopharyngeal swab samples using an integrated smartphone-based centrifugal microfluidic platform
Soares RRG,
Akhtar AS,
Pinto IF,
Lapins N,
Barrett D,
Sandh G,
Yin X,
Pelechano V,
[...], Russom A
[preprint] medRxiv (2020). DOI: 10.1101/2020.11.04.20225888
Innate lymphoid cell composition associates with COVID-19 disease severity
García M,
Kokkinou E,
Carrasco García A,
Parrot T,
Palma Medina LM,
Maleki KT,
Christ W,
Varnaitė R,
[...], Group tKKCS
Clin Transl Immunol 9 (12) (2020). DOI: 10.1002/cti2.1224
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Custódio TF,
Das H,
Sheward DJ,
Hanke L,
Pazicky S,
Pieprzyk J,
Sorgenfrei M,
Schroer MA,
[...], Löw C
Nat Commun 11 (1) (2020). DOI: 10.1038/s41467-020-19204-y
Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA.
Rosendal E,
Wigren J,
Groening R,
Yongdae K,
Nilsson E,
Sharma A,
Espaillat A,
Hanke L,
[...], Forsell M
[preprint] medRxiv (2020). DOI: 10.1101/2020.06.02.20120477
A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies
Zhou S,
Butler-Laporte G,
Nakanishi T,
Morrison D,
Afilalo J,
Afilalo M,
Laurent L,
Pietzner M,
[...], Richards JB
[preprint] Research square (2020). DOI: 10.1101/2020.10.13.20212092
Benchmarking virus concentration methods for quantification of SARS-CoV-2 in raw wastewater
Jafferali MH,
Khatami K,
Atasoy M,
Birgersson M,
Williams C,
Cetecioglu Z
Science of The Total Environment 142939 (2020). DOI: 10.1016/j.scitotenv.2020.142939
SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.
Rudberg A,
Havervall S,
Månberg A,
Jernbom Falk A,
Aguilera K,
Ng H,
Gabrielsson L,
Salomonsson A,
[...], Thålin C
Nat Commun 11 (1) 5064 (2020). DOI: 10.1038/s41467-020-18848-0
Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe/Critical Coronavirus Disease 2019
Yilmaz A,
Marklund E,
Andersson M,
Nilsson S,
Andersson LM,
Lindh M,
Gisslén M
The Journal of Infectious Diseases (2020). DOI: 10.1093/infdis/jiaa632
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
Sekine T,
Perez-Potti A,
Rivera-Ballesteros O,
Strålin K,
Gorin J,
Olsson A,
Llewellyn-Lacey S,
Kamal H,
[...], Buggert M
Cell 183 (1) 158-168.e14 (2020). DOI: 10.1016/j.cell.2020.08.017
Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients.
Frithiof R,
Bergqvist A,
Järhult JD,
Lipcsey M,
Hultström M
Crit Care 24 (1) 587 (2020). DOI: 10.1186/s13054-020-03302-w
Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR.
Smyrlaki I,
Ekman M,
Lentini A,
Rufino de Sousa N,
Papanicolaou N,
Vondracek M,
Aarum J,
Safari H,
[...], Reinius B
Nat Commun 11 (1) 4812 (2020). DOI: 10.1038/s41467-020-18611-5
Critical Illness Polyneuropathy and Myopathy in COVID-19 Patients: A Prospective Observational Intensive Care Unit Cross-Sectional Cohort Study
Frithiof R,
Rostami E,
Kumlien E,
Virhammar J,
Fällmar D,
Hultström M,
Lipcsey M,
Ashton N,
[...], Punga AR
[preprint] Research square (2020). DOI: 10.21203/rs.3.rs-78038/v1
Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro
Akaberi D,
Krambrich J,
Ling J,
Luni C,
Hedenstierna G,
Järhult JD,
Lennerstrand J,
Lundkvist Å
Redox Biology 37 101734 (2020). DOI: 10.1016/j.redox.2020.101734
Antibodies to SARS-CoV-2 and risk of future sickness
Dillner J,
Elfström M,
Blomqvist J,
Eklund C,
Lagheden C,
Nordqvist-Kleppe S,
Hellström C,
Olofsson J,
[...], Conneryd Lundgren K
[preprint] medRxiv (2020). DOI: 10.1101/2020.09.14.20194308
Spatio-Temporal Mutational Profile Appearances of Swedish SARS-CoV-2 during the Early Pandemic.
Ling J,
Hickman RA,
Li J,
Lu X,
Lindahl JF,
Lundkvist Å,
Järhult JD
Viruses 12 (9) (2020). DOI: 10.3390/v12091026
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
Consiglio CR,
Cotugno N,
Sardh F,
Pou C,
Amodio D,
Rodriguez L,
Tan Z,
Zicari S,
[...], Brodin P
Cell (2020). DOI: 10.1016/j.cell.2020.09.016
Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K,
Lipcsey M,
Andersson H,
Pontén E,
Bülow Anderberg S,
Gradin A,
Larsson A,
Lubenow N,
[...], Frithiof R
J Crit Care 60 249-252 (2020). DOI: 10.1016/j.jcrc.2020.08.026
Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients
Hultström M,
Frithiof R,
Eriksson O,
Persson B,
Lipcsey M,
Ekdahl KN,
Nilsson B
Thromb Haemost (2020). DOI: 10.1055/s-0040-1715835
Detection of SARS-CoV-2 using non-commercial RT-LAMP regents and raw samples.
Alekseenko A,
Barrett D,
Pareja-Sanchez Y,
Howard R,
Strandback E,
Ampah-Korsah H,
Rovšnik U,
Zuniga-Veliz S,
[...], Pelechano V
[preprint] medRxiv (2020). DOI: 10.1101/2020.08.22.20179507
Natural killer cell immunotypes related to COVID-19 disease severity.
Maucourant C,
Filipovic I,
Ponzetta A,
Aleman S,
Cornillet M,
Hertwig L,
Strunz B,
Lentini A,
[...], Karolinska COVID-19 Study Group
Sci Immunol 5 (50) (2020). DOI: 10.1126/sciimmunol.abd6832
Blood type A associates with critical COVID-19 and death in a Swedish cohort.
Hultström M,
Persson B,
Eriksson O,
Lipcsey M,
Frithiof R,
Nilsson B
Crit Care 24 (1) 496 (2020). DOI: 10.1186/s13054-020-03223-8
Markers of NETosis and DAMPs are altered in critically ill COVID-19 patients
Huckriede J,
Anderberg SB,
Morales A,
Vries Fd,
Hultström M,
Bergqvist A,
Ortiz JT,
Sels JW,
[...], Nicolaes GAF
[preprint] Research square (2020). DOI: 10.21203/rs.3.rs-52432/v1
A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood
Roxhed N,
Bendes A,
Dale M,
Mattsson C,
Hanke L,
Dodig-Crnkovic T,
Christian M,
Meineke B,
[...], Schwenk JM
[preprint] medRxiv (2020). DOI: 10.1101/2020.07.01.20143966
Rapid Detection of COVID-19 Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) Diagnostic Platform
Yu L,
Wu S,
Hao X,
Dong X,
Mao L,
Pelechano V,
Chen WH,
Yin X
Clin Chem 66 (7) 975-977 (2020). DOI: 10.1093/clinchem/hvaa102
Proteomic blood profiling in mild, severe and critical COVID-19 patients
Patel H,
Ashton NJ,
Dobson RJ,
Anderson LM,
Yilmaz A,
Blennow K,
Gisslen M,
Zetterberg H
[preprint] medRxiv (2020). DOI: 10.1101/2020.06.22.20137216
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Nasi A,
McArdle S,
Gaudernack G,
Westman G,
Melief C,
Rockberg J,
Arens R,
Kouretas D,
[...], Mangsbo S
Toxicology Reports 7 768-771 (2020). DOI: 10.1016/j.toxrep.2020.06.003
NordForsk
| Project title | Principal investigator | PI affiliation | Duration |
|---|---|---|---|
| Addressing the smoking paradox in the etiology of COVID-19 through population-based studies | Maria Rosaria Galanti | Karolinska Institute | 2020 - 2022 |
| Data streams and mathematical modelling pipelines to support preparedness and decision making for COVID-19 and future pandemics | Tom Britton | Stockholm University | 2020 - 2022 |
A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2.
Britton T,
Ball F,
Trapman P
Science 369 (6505) 846-849 (2020). DOI: 10.1126/science.abc6810
Key questions for modelling COVID-19 exit strategies.
Thompson RN,
Hollingsworth TD,
Isham V,
Arribas-Bel D,
Ashby B,
Britton T,
Challenor P,
Chappell LHK,
[...], Restif O
Proc Biol Sci 287 (1932) 20201405 (2020). DOI: 10.1098/rspb.2020.1405
Vinnova
| Project title | Principal investigator | PI affiliation | Duration |
|---|---|---|---|
| Antibodies against SARS-CoV-2 verification of commercially available assays and a nuanced sustainable approach | Anna Fogdell-Hahn | Karolinska Institute | 2020-07-01 - 2021-06-30 |
| Identification of epitopes on SARS-CoV-2 viral particles for rapid development of neutralizing antibodies | Owe Orwar | Oblique Therapeutics AB | 2020-09-01 - 2021-12-31 |
| Validation of a fast and effective Corona diagnostic test for the healthcare system | Yalda Bogestål | RISE Research Institutes of Sweden | 2020-05-11 - 2020-10-30 |
| Targeting the SARS-CoV-2 spike protein to achieve hyperimmunicity and reduce infectivity | Rickard Nordén | Angered Hospital | 2020-10-01 - 2021-03-31 |
| SARS-Cov-2 sensor for rapid sensitive virus detection | Börje Sellergren | SureCapture Technologies AB | 2020-07-01 - 2021-06-30 |
| Evaluating therapeutic potential of integrin 10-selected MSCs in treatment of COVID-19 (ARDS) | Caroline Ehrencrona | Xintela AB | 2020-05-08 - 2020-11-30 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Susek KH,
Gran C,
Ljunggren HG,
Alici E,
Nahi H
Eur J Haematol. 105 (6) 751-754 (2020). DOI: 10.1111/ejh.13502
SARS-CoV-2 serological tests can generate false positive results for samples from patients with chronic inflammatory diseases
Kharlamova N,
Dunn N,
Bedri SK,
Jerling S,
Almgren M,
Faustini F,
Gunnarsson I,
Rönnelid J,
[...], Fogdell-Hahn A
[preprint] medRxiv (2020). DOI: 10.1101/2020.11.13.20231076
Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA.
Rosendal E,
Wigren J,
Groening R,
Yongdae K,
Nilsson E,
Sharma A,
Espaillat A,
Hanke L,
[...], Forsell M
[preprint] medRxiv (2020). DOI: 10.1101/2020.06.02.20120477
Horizon 2020
| Project title | Principal investigator | PI affiliation | Duration |
|---|---|---|---|
| Fighting-off coronavirus (SARS-CoV-2) with broad-spectrum antivirals: establishing animal viral challenge model | Anna-Lena Spetz | Stockholm University | 2020-04-01 - 2022-03-31 |
| Antibody therapy against coronavirus (COVID-19) | Qiang Pan Hammarström, Harold Marcotte, Lennart Hammarström | Karolinska Institute | 2020-04-01 - 2022-03-31 |
| Rapid therapy development through Open Coronavirus Vaccine Platform | Matti Sällberg, Gustaf Ahlén | Karolinska Institute | 2020-04-01 - 2022-03-31 |
| Nanobodies and antibodies against 2019-nCoV | Benjamin Murrell, Gerald McInerney, Gunilla Karlsson Hedestam | Karolinska Institute | 2020-04-01 - 2022-03-31 |
Sustained prothrombotic changes in COVID-19 patients four months after hospital discharge
von Meijenfeldt F,
Havervall S,
Adelmeijer J,
Lundström A,
Magnusson M,
Mackman N,,
Thålin C,
Lisman T
Blood Advances: in press (2021).
Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids.
Pettke A,
Tampere M,
Pronk R,
Wallner O,
Falk A,
Warpman Berglund U,
Helleday T,
Mirazimi A,
[...], Puumalainen MR
Viruses 13 (1) (2020). DOI: 10.3390/v13010037
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden
Dopico XC,
Muschiol S,
Christian M,
Hanke L,
Sheward DJ,
Grinberg NF,
Bogdanovic G,
Mcinerney GM,
[...], Karlsson Hedestam GB
[preprint] medRxiv (2020). DOI: 10.1101/2020.12.24.20248821
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.
Moliner-Morro A,
J Sheward D,
Karl V,
Perez Vidakovics L,
Murrell B,
McInerney GM,
Hanke L
Biomolecules 10 (12) (2020). DOI: 10.3390/biom10121661
Point-of-care detection of SARS-CoV-2 in nasopharyngeal swab samples using an integrated smartphone-based centrifugal microfluidic platform
Soares RRG,
Akhtar AS,
Pinto IF,
Lapins N,
Barrett D,
Sandh G,
Yin X,
Pelechano V,
[...], Russom A
[preprint] medRxiv (2020). DOI: 10.1101/2020.11.04.20225888
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Custódio TF,
Das H,
Sheward DJ,
Hanke L,
Pazicky S,
Pieprzyk J,
Sorgenfrei M,
Schroer MA,
[...], Löw C
Nat Commun 11 (1) (2020). DOI: 10.1038/s41467-020-19204-y
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L,
Vidakovics Perez L,
Sheward DJ,
Das H,
Schulte T,
Moliner-Morro A,
Corcoran M,
Achour A,
[...], McInerney GM
Nat Commun 11 (1) 4420 (2020). DOI: 10.1038/s41467-020-18174-5
SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses
Mandolesi M,
Sheward DJ,
Hanke L,
Ma J,
Pushparaj P,
Perez Vidakovics L,
Kim C,
Loré K,
[...], Murrell B
[preprint] bioRxiv (2020). DOI: 10.1101/2020.07.31.228486
Discriminative Bayesian Serology: Counting Without Cutoffs
Christian M,
Murrell B
[preprint] (2020). DOI: 10.1101/2020.07.14.202150
A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood
Roxhed N,
Bendes A,
Dale M,
Mattsson C,
Hanke L,
Dodig-Crnkovic T,
Christian M,
Meineke B,
[...], Schwenk JM
[preprint] medRxiv (2020). DOI: 10.1101/2020.07.01.20143966
Hjärt-Lungfonden
*NB: Project titles of this funder are only available in Swedish.